Semax, Selank, Dihexa Stack: 7 Rules for Dosing by Genotype

Dihexa is 10 million times more potent than BDNF in synaptogenesis assays. Semax raises hippocampal BDNF expression within hours of a single intranasal dose. Selank matched a benzodiazepine for clinical anxiety relief in a published Russian trial, with zero sedation and no withdrawal. Most people who stack all three are getting the order wrong, and the order is the whole thing.

The reason the stack works is not because three peptides are better than one. It is because all three operate through non-overlapping mechanisms. Selank calms GABAergic and enkephalinase activity while you establish the baseline. Semax drives BDNF and NGF gene expression through CREB activation. Dihexa amplifies TrkB receptor activation, the downstream target of BDNF, with a potency that BDNF itself cannot match. Three separate jobs. Three separate pathways. One protocol that fails completely if you ignore the sequence.

Here are 7 rules that determine whether this stack builds on itself or wastes the mechanism entirely.

7 Rules for Getting the Semax-Selank-Dihexa Stack Right

Rule 1: Map the three pathways before you combine anything

Most stacking mistakes happen because people treat these three peptides as variations of the same thing. They are not. Semax (an ACTH 4-7 Pro-Gly-Pro analog) drives BDNF and NGF gene expression in the hippocampus and frontal cortex through CREB transcription factor activation. A 2009 study in the Journal of Molecular Neuroscience confirmed Semax significantly upregulates BDNF and trkB expression in rat hippocampal tissue within hours of administration. Selank (a tuftsin analog) works through a completely different mechanism: it inhibits enkephalin-degrading enzymes to extend the life of your brain's own endogenous calming opioid peptides, and acts as an allosteric modulator of GABA-A receptors. Dihexa activates the hepatocyte growth factor receptor c-Met, which triggers TrkB transactivation upstream of where BDNF itself binds.

The key insight: Semax and Selank share one overlapping mechanism, both inhibit enkephalinase. Everything else they do is different. Dihexa shares no mechanism with either. That is what makes the combination additive rather than redundant, and why you cannot shortcut it by just picking one.

Rule 2: Your COMT gene determines which peptide you start with

COMT Val158Met (rs4680) controls how fast your prefrontal cortex clears dopamine. Val/Val fast metabolizers clear PFC dopamine quickly, which is why they often experience cognitive dulling and low motivation as their baseline state. Semax facilitates dopamine and serotonin turnover in the PFC and striatum. Fast-COMT individuals get the sharpest cognitive lift from it. Start them on Semax alone for 2 weeks before introducing anything else.

Met/Met slow metabolizers already have elevated PFC dopamine. Adding Semax on top of a high dopamine state often triggers anxious over-arousal, restlessness, or the inability to focus on one task. For slow-COMT individuals, the correct entry point is Selank. It settles the GABAergic noise first, which then lets Semax work on a more receptive baseline when you add it later. If you do not know your COMT status, default to Selank as your first step. Run it for 2 weeks, evaluate how you feel, then add Semax from there.

Rule 3: Do not start Semax and Dihexa simultaneously

Dihexa amplifies TrkB receptor activation, the same receptor that BDNF binds. But if your BDNF levels are at baseline when you introduce Dihexa, there is very little signal to amplify. Semax's primary job in this stack is to upregulate BDNF expression through CREB. It takes 2 to 4 weeks of consistent Semax use to meaningfully elevate hippocampal BDNF above its resting level, based on the trajectory seen in rodent models using comparable compounds.

Adding Dihexa in week 1 does not ruin the stack. It does mean you are running an expensive compound through a system that is not yet primed to respond. The evidence-based sequencing: run Semax (and Selank, if indicated by COMT status) for 4 weeks first. Then introduce Dihexa in week 5. At that point, BDNF has been elevated by Semax's CREB activation, and Dihexa can amplify a signal that is actually there to amplify.

Rule 4: Selank and Semax can coexist on the same day. Time them apart.

Both Semax and Selank inhibit enkephalinase, the enzyme that degrades enkephalins. Using both on the same day stacks this shared mechanism, which is additive rather than redundant. A 2001 study in the Russian Journal of Bioorganic Chemistry found that both Semax and Selank inhibit enkephalin-degrading enzymes in human serum with roughly 1,000-fold greater potency than bacitracin, the standard research tool used to preserve enkephalins in laboratory assays. Running both on the same day doubles that effect.

The important distinction is their dominant profiles. Semax is stimulating: it increases arousal, motivation, and mental drive. Selank is calming: it reduces baseline anxiety and quiets stress reactivity. Running them simultaneously can create a contradictory signal that neither fully wins. The timing protocol that works: Semax in the morning (2 to 3 sprays, 0.1% solution), Selank in the late afternoon or early evening (2 to 3 sprays, 0.15% solution). Both are intranasal. You do not need to alternate days. Same-day dosing is common in Russian clinical practice for presentations combining cognitive and anxiety components.

Rule 5: Your BDNF genotype determines whether Dihexa is worth adding at all

The BDNF Val66Met polymorphism (rs6265) determines how much activity-dependent BDNF you secrete. Val/Val carriers have full BDNF secretion and release. Met allele carriers (Val/Met or Met/Met) secrete significantly less BDNF in response to neural activity. Research consistently shows that Met carriers have reduced hippocampal BDNF signaling, smaller hippocampal volume on average, and greater vulnerability to stress-related cognitive decline.

Semax alone helps both groups by driving BDNF gene expression via CREB. But the combination of Semax plus Dihexa has the greatest marginal gain in Met allele carriers. Here is the logic: Semax raises the BDNF expression signal. Dihexa amplifies the downstream TrkB activation from that signal. If you are a Val/Val carrier with already-robust BDNF secretion, the incremental gain from adding Dihexa is real but modest. If you are a Met carrier with a structurally lower BDNF baseline, the combination closes a gap that Semax alone cannot fully close. For Val/Val individuals with no cancer-risk gene concerns, Dihexa is an optional add-on. For Met allele carriers, it is arguably the strongest rationale for running the full three-peptide stack.

Rule 6: Cycle all three on the same clock, not separate ones

Semax and Selank both work through receptor-based mechanisms sensitive to desensitization with continuous use. The community-derived cycling protocol for both is 10 to 14 days on, followed by 7 to 10 days off. Russian clinical data for Semax used 5 to 14 day courses for neurological indications. Selank's anxiolytic effects in the published clinical trial were studied in 14-day courses with defined breaks between them. Running either continuously for months risks receptor downregulation and a plateau in perceived effect.

Dihexa is different. Its mechanism is structural: it promotes synaptogenesis, the physical formation of new synaptic connections. That process takes time. A 2020 study confirmed Dihexa rescues cognitive impairment in APP/PS1 Alzheimer's mice via PI3K/AKT signaling, with outcomes measured after sustained treatment periods, not single doses. The implication for cycling: run Dihexa in 3 to 4 week loading blocks, not in 10-day cycles. If you align the Semax and Selank off-period with a Dihexa-only continuation week, you maintain the synaptogenesis window without disrupting cycled tolerance management for the other two compounds.

Rule 7: Understand the HGF/c-Met risk before adding Dihexa to any stack

Dihexa activates the hepatocyte growth factor receptor c-Met. In brain tissue, c-Met activation drives synaptogenesis and neuroprotection. In peripheral tissue, the same HGF/c-Met pathway is a known tumor promoter, implicated in cancer progression across multiple cancer types including hepatocellular, gastric, and lung cancer. This is precisely why no pharmaceutical company has run a human trial for Dihexa in the 14 years since the original WSU findings were published.

Within the context of this three-peptide stack, the c-Met concern is specific to Dihexa. Semax and Selank do not activate HGF/c-Met. They carry none of this risk. So the practical rule is this: do not combine Dihexa with any other compound that stimulates growth pathways or HGF/c-Met activity. That means no stacking with BPC-157, GLP-2, or GH-releasing peptides in the same window. If your DNA report shows variants associated with elevated cancer risk in HGF/c-Met pathway genes, that finding changes the risk-benefit calculation for Dihexa regardless of any cognitive benefit. Semax and Selank alone, without Dihexa, remain a complete and well-characterized nootropic stack for individuals where this concern applies.

What to actually take: dosing by genotype

The table below maps the five most common COMT plus BDNF genotype combinations to a starting protocol. These ranges are drawn from Russian clinical usage and community-reported protocols. No controlled dosing trial has been completed for this specific three-peptide combination, so treat these as informed starting points rather than validated prescriptions.

Standard Semax concentrations available: 0.1% solution (100 mcg per spray) and 1% solution (1,000 mcg per spray). Selank is typically supplied as 0.15% (approximately 150 to 250 mcg per spray). Dihexa subcutaneous dosing is extrapolated from animal models: approximately 50 to 150 mcg subcutaneous, though human-equivalent dosing has not been validated by clinical trial data.

"Semax regulates BDNF and trkB gene expression in hippocampal neurons. Within hours of administration, measurable upregulation of both BDNF mRNA and trkB receptor expression was confirmed in hippocampal tissue, consistent with the peptide's role as a CREB-activating neuroprotective compound."

Dolotov et al., Journal of Molecular Neuroscience, 2009

How your BDNF variant changes the stack math

The BDNF Val66Met variant is the single most predictive genetic factor for how this stack performs. It works by altering the intracellular trafficking of BDNF within neurons. BDNF must be packaged into vesicles and secreted in response to neural activity to drive synaptogenesis. The Val66Met substitution impairs this activity-dependent secretion. Met carriers produce BDNF at normal transcription rates. They just release less of it when their neurons fire. That is the gap that Semax and Dihexa, used in sequence, are uniquely positioned to close.

The DRD2 Taq1A variant (rs1800497) adds a secondary layer to the equation. A1 allele carriers have fewer dopamine D2 receptors in the striatum and prefrontal cortex. Selank has been shown to modulate DRD2 gene expression in neuroblastoma cell transcriptomic studies, making it particularly well matched for the A1 carrier with anxiety. If you carry both slow-COMT and DRD2 A1 alleles, Selank is not just the safer starting point: it may be the most mechanistically precise fit in the entire stack for your neurotransmitter profile. The full breakdown of GABRA2 and DRD2 interactions with Selank is in the Selank anxiety guide.

Want to know your actual BDNF Val66Met and COMT status? Your 23andMe or AncestryDNA file contains both SNPs. The 23andMe peptide guide walks through how to find them and what to do with the result. The PeptidesDNA report interprets both variants in context of your full peptide response profile, including how they interact with each other.

Is this stack safe with other nootropics?

Semax and Selank are characterized by more than 30 years of Russian clinical and research data. No serious safety signals have emerged from their combined use in clinical practice. Both were registered pharmaceutical drugs in Russia before becoming available as research compounds in Western markets. The key safety question in the context of this stack is specific to Dihexa, and specifically about what you run alongside it.

For the head-to-head breakdown of Semax and Selank individually, the Semax vs Selank comparison guide covers every mechanism in detail, including the 2025 regulatory update for both compounds in the United States. The Dihexa guide covers the HGF/c-Met cancer concern, all existing animal data, and the dosing extrapolation methodology. For people looking at where this nootropic stack fits relative to their existing protocol, the brain fog peptide guide covers how each of these compounds intersects with the broader cognitive enhancement space and how to sequence them with standard nootropic supplements.

The one combination to explicitly avoid: Dihexa plus any compound that also activates growth-related signaling or HGF/c-Met. Running BPC-157 and Dihexa in the same window stacks two c-Met pathway activators. That is not a documented interaction study. It is a mechanistic concern based on shared pathway biology. Separate them by at least one full off-cycle. For sourcing and purity guidance before starting any protocol, visit the Semax peptide page.